OCGN OCUGEN INC US FDA Inspections 8-K Filing 2024 - FDA Notification for Expanded Access Program Ocugen, Inc. received notification from the FDA to begin its expanded access program for the treatment of retinitis pigmentosa with OCU400.Get access to all SEC 8-K filings of the OCUGEN INC